Peter  Radovich net worth and biography

Peter Radovich Biography and Net Worth

President & Chief Operating Officer of Mirum Pharmaceuticals

Peter Radovich currently serves as president and chief operating officer at Mirum where he is responsible for commercial, corporate development, chemistry, manufacturing and controls (CMC), and supply chain. Peter joined Mirum in April 2020 as chief operating officer with more than 20 years of operational experience in the biopharmaceutical industry.

Prior to Mirum, he served as executive vice president, operations at Global Blood Therapeutics (GBT) from 2014 to 2020, responsible for technical operations, supply chain, program management and leadership, quality assurance, and commercial strategy and analytics functions. From 2006 to 2014, Peter worked at Onyx Pharmaceuticals, Inc. (now Amgen, Inc.) serving in a variety of roles including vice president, program leadership, as well as commercial and corporate strategy roles. Prior to Onyx, Peter held product marketing positions at Chiron Corporation (now Novartis AG).

Peter is also a board member at Rain Therapeutics Inc., a precision oncology company. Peter received an M.B.A. from Washington University in St. Louis and his undergraduate degree in biology and chemistry from Texas Christian University.

What is Peter Radovich's net worth?

The estimated net worth of Peter Radovich is at least $761,817.60 as of March 17th, 2025. Mr. Radovich owns 18,672 shares of Mirum Pharmaceuticals stock worth more than $761,818 as of April 26th. This net worth approximation does not reflect any other assets that Mr. Radovich may own. Additionally, Mr. Radovich receives an annual salary of $881,800.00 as President & Chief Operating Officer at Mirum Pharmaceuticals. Learn More about Peter Radovich's net worth.

How old is Peter Radovich?

Mr. Radovich is currently 46 years old. There are 5 older executives and no younger executives at Mirum Pharmaceuticals. The oldest executive at Mirum Pharmaceuticals is Mr. Eric H. Bjerkholt M.B.A., Chief Financial Officer, who is 64 years old. Learn More on Peter Radovich's age.

What is Peter Radovich's salary?

As the President & Chief Operating Officer of Mirum Pharmaceuticals, Inc., Mr. Radovich earns $881,800.00 per year. The highest earning executive at Mirum Pharmaceuticals is Mr. Christopher Peetz, Co-Founder, CEO and Director, who commands a salary of $1,310,000.00 per year. Learn More on Peter Radovich's salary.

How do I contact Peter Radovich?

The corporate mailing address for Mr. Radovich and other Mirum Pharmaceuticals executives is 950 TOWER LANE SUITE 1050, FOSTER CITY CA, 94404. Mirum Pharmaceuticals can also be reached via phone at (650) 667-4085 and via email at ir@mirumpharma.com. Learn More on Peter Radovich's contact information.

Has Peter Radovich been buying or selling shares of Mirum Pharmaceuticals?

Peter Radovich has not been actively trading shares of Mirum Pharmaceuticals during the past quarter. Most recently, Peter Radovich sold 7,879 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $44.21, for a transaction totalling $348,330.59. Following the completion of the sale, the chief operating officer now directly owns 18,672 shares of the company's stock, valued at $825,489.12. Learn More on Peter Radovich's trading history.

Who are Mirum Pharmaceuticals' active insiders?

Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Mirum Pharmaceuticals?

During the last twelve months, Mirum Pharmaceuticals insiders bought shares 3 times. They purchased a total of 1,680 shares worth more than $74,700.35. During the last twelve months, insiders at the sold shares 17 times. They sold a total of 172,113 shares worth more than $7,304,987.14. The most recent insider tranaction occured on March, 17th when SVP Jolanda Howe sold 57,606 shares worth more than $2,554,826.10. Insiders at Mirum Pharmaceuticals own 22.9% of the company. Learn More about insider trades at Mirum Pharmaceuticals.

Information on this page was last updated on 3/17/2025.

Peter Radovich Insider Trading History at Mirum Pharmaceuticals

See Full Table

Peter Radovich Buying and Selling Activity at Mirum Pharmaceuticals

This chart shows Peter Radovich's buying and selling at Mirum Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$500k$0$500kTotal Insider BuyingTotal Insider Selling

Mirum Pharmaceuticals Company Overview

Mirum Pharmaceuticals logo
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $40.80
Low: $39.84
High: $41.04

50 Day Range

MA: $44.12
Low: $38.39
High: $53.16

2 Week Range

Now: $40.80
Low: $23.83
High: $54.23

Volume

186,097 shs

Average Volume

521,493 shs

Market Capitalization

$2.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1